Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stellate Ganglion Block in Dysphagic Patients With Bulbar Palsy After Ischemic Stroke
NCT06319534Completed
- Sponsor
- Zengxi Biotechnology
- Start
- Mar 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of lidocaine in bulbar palsy (PBP) and dysphagia (2 arms), sponsored by Zengxi Biotechnology. Primary endpoint: Modified Barium Swallow Impairment Profile at day 60. Started Mar 2024; status: completed.
02
Drugs
lidocaine
03
Conditions
bulbar palsy (PBP)dysphagia
Beyond the preview
Go deeper on NCT06319534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06319534.